CXCR2 and breast cancer: Such observations are in line with a recent publication reporting that the CXCR2 inhibitor could significantly decrease the trafficking of MDSC in metastatic LN associated with an enhanced accumulation of NK cells in orthotopic breast cancer mouse model [51].